RTTR Ritter Pharmaceuticals, Inc.

0.82
0  -3%
Previous Close 0.85
Open 0.85
Price To book 2.41
Market Cap 9.54M
Shares 11,619,000
Volume 345,990
Short Ratio 2.99
Av. Daily Volume 492,702

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data released March 28, 2017. Primary endpoint met. End of Phase 2 meeting with FDA planned
RP-G28
Lactose intolerance

Latest News

  1. Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities
  2. Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
  3. Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  4. Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
  5. Ritter Pharmaceuticals to Ring Today's Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month
  6. Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) to Ring The Nasdaq Stock Market Closing Bell
  7. Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome
  8. Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors
  9. Penny Stocks to Watch for January 2016
  10. Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences
  11. Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
  12. Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
  13. Why These Five Stocks Are Trending Today
  14. Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28
  15. Ritter Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
  16. Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
  17. Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance
  18. Ritter Pharmaceuticals Issued Two New Patents